Precipio (NASDAQ:PRPO) Share Price Crosses Above 50 Day Moving Average – Here’s Why

Precipio, Inc. (NASDAQ:PRPO) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $25.16 and traded as high as $26.21. Precipio shares last traded at $26.00, with a volume of 33,753 shares.

Analyst Ratings Changes

PRPO has been the topic of a number of research reports. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Precipio Stock Up 2.9%

The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $25.16 and a 200 day simple moving average of $25.10. The firm has a market capitalization of $46.54 million, a PE ratio of -55.32 and a beta of 1.27.

Precipio (NASDAQ:PRPO) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. The company had revenue of $6.71 million for the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.73%.

Institutional Investors Weigh In On Precipio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Precipio during the third quarter valued at about $194,000. Finally, Topline Capital Management LLC purchased a new stake in shares of Precipio during the third quarter worth about $1,158,000. 10.45% of the stock is currently owned by institutional investors.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.